You are receiving this message as a subscriber to the FDA HIV/AIDS electronic list serve. The purpose of the list serve is to relay important information about HIV/AIDS-related products and issues, including product approvals, significant labeling changes, safety warnings, notices of upcoming public meetings and alerts to proposed regulatory guidances for comment.

To UNSUBSCRIBE from this list, or change your e-mail address, please go to http://list.nih.gov/cgi-bin/wa?SUBED1=fda-hiv-aids&A=1

Please do not reply to this message.
_______________________________________________

Some HIV-infected patients may have interrupted their antiretroviral therapy and other medications due to the recent hurricane disasters.  The following link provides some guidance to the general practitioners attending to the medical needs of displaced HIV-infected adult or pediatric patients who have not yet secured HIV care in the local area.

Management of antiretroviral therapy is complex and should best be done with the assistance of specialized clinicians.

To see the recommendations go to:

http://aidsinfo.nih.gov/guidelines/disaster/2EssentialsforManagingHIV1ap.pdf

Medical consultation may also be available at specific local or regional HIV clinics or via the 24-hour NIH Medical Consultation Services at 1-866-887-2842 or the National HIV Telephone Consultation Service: at 1-800-933-3413.

The recommendations were prepared by:
The Panel on Clinical Practices for Treatment of HIV Infection (Adult and Adolescent HIV Treatment Guidelines Panel)
The Perinatal HIV Guidelines Working Group
The Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children
USPHS/IDSA Prevention and Treatment of Opportunistic Infections Working Groups

Richard Klein
HIV/AIDS Program Director
Office of Special Health Issues
Food and Drug Administration

An archive of past list serve announcements is available on the FDA web site at http://www.fda.gov/oashi/aids/listserve/archive.html